The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Retrieved on:
Monday, November 1, 2021
Dai, Fibrosis, CREB-binding protein, Neurology, Sustainable Development Goal 3, Cancer, Research, Organogenesis, Cell proliferation, RAS, MYC, Atomic mass, Merck, PRISM, Sustainable Development Goals, CBP, Patient, Drug discovery, Achievement, Oncology, Differentiable function, POC, Hepatocellular carcinoma, APC, Merck & Co., Wnt signaling pathway, Senior, Gastrulation, CEO, Biomarker, Mammal, Drosophila, Morphogenesis, Adenomatous polyposis coli, Pembrolizumab, PCP, Gene expression, Pharmaceutical industry
The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery.
Key Points:
- The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery.
- E7386 is a CBP / beta-catenin inhibitor that inhibits CBP and beta-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression.
- (1)
Based on the POC achievement, Eisai has initiated a phase Ib/II clinical trial (Study 201) of E7386 in combination with anti-PD-1 therapy pembrolizumab for solid tumors in Japan. - E7386 is a CBP / beta-catenin inhibitor that inhibits protein-protein interactions between the transcription coactivator CBP and beta-catenin, and regulates the Wnt signaling-dependent gene expression.